Page last updated: 2024-12-06

n-(2-hydroxyethyl)nicotinamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N-(2-hydroxyethyl)nicotinamide (HEN) is a derivative of nicotinamide. It is a potent NAD+ precursor and has been shown to have various pharmacological effects, including neuroprotective, anti-inflammatory, and antioxidant properties. HEN has been investigated for its potential therapeutic benefits in various neurological disorders, such as Alzheimer's disease, Parkinson's disease, and stroke. Research has shown that HEN can enhance cognitive function and protect against neuronal damage in animal models of these diseases. HEN is typically synthesized through the reaction of nicotinamide with 2-chloroethanol or 2-bromoethanol in the presence of a base. The synthesis involves an SN2 reaction, where the nucleophilic nitrogen atom of nicotinamide attacks the electrophilic carbon atom of the haloalcohol, resulting in the formation of HEN. The importance of HEN lies in its ability to increase NAD+ levels, a crucial coenzyme involved in numerous metabolic pathways. NAD+ plays a vital role in cellular energy production, DNA repair, and signaling pathways. By increasing NAD+ levels, HEN may promote mitochondrial function, reduce oxidative stress, and enhance neuronal survival. HEN's ability to cross the blood-brain barrier makes it a promising candidate for the treatment of neurological disorders. Currently, preclinical studies are ongoing to evaluate the efficacy and safety of HEN as a potential therapeutic agent for various neurological conditions.'

N-(2-hydroxyethyl)nicotinamide: metabolite of SG-75; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID72663
CHEMBL ID3264036
SCHEMBL ID62572
MeSH IDM0096998

Synonyms (38)

Synonym
6265-73-2
nsc-33142
nsc33142
OPREA1_258812
OPREA1_336986
n-(2-hydroxyethyl)pyridine-3-carboxamide
STK498482
sg 86
AKOS000283563
n-(2-hydroxyethyl)nicotinamide
EN300-80598
sg-86
mhh3ut8grp ,
nsc 33142
3-pyridinecarboxamide, n-(2-hydroxyethyl)-
unii-mhh3ut8grp
n-(2-hydroxyethyl)nitotinamide
CHEMBL3264036
SCHEMBL62572
FS-3101
n-(2-hydroxyethyl)-nicotinamide
n-hydroxy ethyl nicotinamide
n-(2-hydroxyethyl)-3-pyridinecarboxamide
n-(2-hydroxy-ethyl)-nicotinamide
pyridine-3-carboxamide, n-(2-hydroxyethyl)-
n-(2-hydroxyethyl)nicotinamide #
DTXSID30211708
mfcd00547113
2-(2-bromoethyl)benzimidazole
Z31725207
A868410
3-(2-hydroxyethyl)carbamoylpyridine
n-nicotinoylethanolamine
nicotinamide, n-(2-hydroxyethyl)-
n-nicotinoyl-2-aminoethanol
SY107943
CS-0149652
nicorandil amide

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" The validated method was successfully applied to a pharmacokinetic study after per os administration of nicorandil in rats."( Simultaneous quantitation of nicorandil and its denitrated metabolite in plasma by LC-MS/MS: application for a pharmacokinetic study.
Araujo, DP; Bastos, LF; César, IC; Coelho, Mde M; de Fátima, Â; Godin, AM; Guidine, PA; Pianetti, GA, 2011
)
0.37
" Pharmacokinetic parameters of nicorandil and its isomers, as well as the plasma concentrations of the corresponding denitrated metabolites and also nicotinamide and nitrite were determined."( Synthesis, antinociceptive activity and pharmacokinetic profiles of nicorandil and its isomers.
Almeida, MO; Araujo, DP; César, IC; Coelho, MM; de Fátima, A; Dutra, MM; Godin, AM; Machado, RR; Menezes, RR; Oliveira, FC; Pianetti, GA; Santos, DA; Santos, JR, 2014
)
0.4
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID1139127Antinociceptive activity in Swiss mouse assessed as inhibition of formaldehyde-induced nociceptive response in right hind paw at 50 to 150 mg/kg, po administered 5 mins followed by formaldehyde challenge measured for 15 to 30 mins2014Bioorganic & medicinal chemistry, May-01, Volume: 22, Issue:9
Synthesis, antinociceptive activity and pharmacokinetic profiles of nicorandil and its isomers.
AID1139137Cmax in Swiss mouse treated with nicorandil at 100 mg/kg, po by LC-MS/MS analysis2014Bioorganic & medicinal chemistry, May-01, Volume: 22, Issue:9
Synthesis, antinociceptive activity and pharmacokinetic profiles of nicorandil and its isomers.
AID1139146AUC (0 to infinity) in Swiss mouse treated with nicorandil at 100 mg/kg, po by LC-MS/MS analysis2014Bioorganic & medicinal chemistry, May-01, Volume: 22, Issue:9
Synthesis, antinociceptive activity and pharmacokinetic profiles of nicorandil and its isomers.
AID1139126Antinociceptive activity in Swiss mouse assessed as inhibition of formaldehyde-induced nociceptive response in right hind paw at 50 to 150 mg/kg, po administered 5 mins followed by formaldehyde challenge measured over 5 mins2014Bioorganic & medicinal chemistry, May-01, Volume: 22, Issue:9
Synthesis, antinociceptive activity and pharmacokinetic profiles of nicorandil and its isomers.
AID1139140Tmax in Swiss mouse treated with nicorandil at 100 mg/kg, po by LC-MS/MS analysis2014Bioorganic & medicinal chemistry, May-01, Volume: 22, Issue:9
Synthesis, antinociceptive activity and pharmacokinetic profiles of nicorandil and its isomers.
AID1139149Half life in Swiss mouse treated with nicorandil at 100 mg/kg, po by LC-MS/MS analysis2014Bioorganic & medicinal chemistry, May-01, Volume: 22, Issue:9
Synthesis, antinociceptive activity and pharmacokinetic profiles of nicorandil and its isomers.
AID1139143AUC (0 to t) in Swiss mouse treated with nicorandil at 100 mg/kg, po by LC-MS/MS analysis2014Bioorganic & medicinal chemistry, May-01, Volume: 22, Issue:9
Synthesis, antinociceptive activity and pharmacokinetic profiles of nicorandil and its isomers.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (33.33)18.7374
1990's4 (33.33)18.2507
2000's2 (16.67)29.6817
2010's2 (16.67)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.09

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.09 (24.57)
Research Supply Index2.56 (2.92)
Research Growth Index4.66 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.09)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]